Friday, September 29, 2023


Biotechnology News Magazine

Oncimmune Reports Agreements Signed with Roche and Cedars-Sinai to Profile Patients Using Oncimmune’s Novel Infectious Disease Panel

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

April 6, 2021

Oncimmune Holdings plc today announces that it has signed two separate agreements with Roche Pharmaceuticals (“Roche”) and Cedars-Sinai Medical Center (“Cedars-Sinai”), in each case to use the Company’s newly developed and proprietary Infectious Disease panel.

On 6 October 2020, Oncimmune announced the award of UK Government funding for the development and validation of an Infectious Disease NavigAID™ panel under the IMmunity Profiling of pAtients with COVID-19 for Therapy and Triage (“IMPACTT”) program.

Utilizing the data from this and other work, the Company’s current SeroTag™ research panel has been tailored to predict COVID-19 disease severity and therapeutic response to the virus and the effectiveness of vaccines and other repurposed therapeutics as a treatment against the disease. Both of these substantial new contracts will utilize this research tool to profile patient samples in search of immune-related signatures in COVID-19 patients.

For Roche, Oncimmune will utilize its Infectious Disease panel to profile antibody and autoantibody responses in all patient samples from the Roche COVACTA trial, to look for immune signals of response, non-response and adverse events. The COVACTA trial was set up to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia. The contract also includes an option to extend to IgA and IgM antibody profiling which will substantially increase the value of the contract.

In October 2020, Oncimmune also announced that it had entered into an agreement with Cedars-Sinai in Los Angeles, a world-leading medical research organization, to provide antibody profiling in COVID-19 samples as biomarkers for this disease. Following on from this first project, Cedars-Sinai has agreed to expand its collaborative COVID-19 program to study a unique cohort of patients.

Dr. Adam M Hill, CEO of Oncimmune said: “We are delighted to be strengthening our partnership with Roche and Cedars-Sinai through these two very important projects. As the world shifts its focus to recovering from the pandemic, we are seeing continued interest in Oncimmune’s infectious disease offering.”

He added, “Today’s announcement is further validation of the importance of our Infectious Disease panel in supporting both clinical research and the development of vaccines and therapeutics. We are also experiencing substantial interest in our immuno-oncology and autoimmune activities, which together with our infectious disease offering, provides us with confidence in the continued growth of ImmunoINSIGHTS.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine